- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
Patent holdings for IPC class A61K 31/436
Total number of patents in this class: 2856
10-year publication summary
|
238
|
244
|
235
|
260
|
244
|
248
|
256
|
200
|
207
|
158
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Selecta Biosciences, Inc. | 190 |
87 |
| Novartis AG | 10656 |
75 |
| Abraxis BioScience, LLC | 206 |
55 |
| Lutonix, Inc. | 65 |
41 |
| The Regents of the University of California | 20230 |
36 |
| The Board of Trustees of the Leland Stanford Junior University | 6509 |
33 |
| Santen Pharmaceutical Co., Ltd. | 599 |
23 |
| The Trustees of the University of Pennsylvania | 4376 |
22 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3205 |
21 |
| Terumo Kabushiki Kaisha | 5624 |
19 |
| Duke University | 3103 |
19 |
| Board of Regents, The University of Texas System | 5917 |
18 |
| Pfizer Inc. | 3397 |
17 |
| The Johns Hopkins University | 5739 |
17 |
| Icahn School of Medicine at Mount Sinai | 971 |
16 |
| Pharmacyclics LLC | 243 |
16 |
| Revolution Medicines, Inc. | 262 |
16 |
| Palvella Therapeutics, Inc. | 22 |
16 |
| Veloxis Pharmaceuticals Inc. | 41 |
16 |
| OrphAI Therapeutics Inc. | 40 |
16 |
| Other owners | 2277 |